Keyphrases
Inhibitor Therapy
100%
Epidermal Growth Factor Receptor Inhibitors
100%
Dermatologic Toxicity
100%
Confidence Interval
85%
Rash
71%
Radiation Dermatitis
71%
Radiotherapy
42%
Mucositis
42%
Phase II Trial
28%
Safety Concerns
14%
Management Strategy
14%
American Society
14%
Solid Tumors
14%
Quality of Life
14%
Relative Risk
14%
Dermatitis
14%
Random Effects
14%
Anecdotal Evidence
14%
Overall Effect
14%
Oncology
14%
MEDLINE
14%
Fixed Effects Model
14%
Embase
14%
Phase 1 Trial
14%
Incidence Rate
14%
American Society of Clinical Oncology
14%
Locoregional Control
14%
Risk Ratio
14%
Cochrane Collaboration
14%
Combined Regimen
14%
Collaborative Groups
14%
Reduced Mortality
14%
Reporting Strategies
14%
Toxicity Data
14%
Chemoradiation
14%
Medicine and Dentistry
Dermatological Agent
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Exanthem
71%
Radiation Dermatitis
71%
Mucositis
71%
Radiation Therapy
57%
Solid Malignant Neoplasm
14%
Quality of Life
14%
Oncology
14%
Clinical Oncology
14%
Chemoradiotherapy
14%
Dermatitis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Dermatological Agent
100%
Rash
71%
Mucosa Inflammation
71%
Solid Malignant Neoplasm
14%
Dermatitis
14%
Chemoradiation Therapy
14%